Jasper Therapeutics is enabling cures through stem cell transplantation. The company is testing a c-Kit/ CD119 antibody (JSP-191) which is currently in late-stage clinical testing for Hematopoietic Cell Transplantation (HCT) associated with Severe Combined Immunodeficiency and MDS/AML. The humanized monoclonal antibody creates a niche space in the bone marrow by safely and specifically targeting and depleting blood forming stem cells and progenitor cells. Jasper is also working on engineered stem cell approaches to potentially treat cancer and autoimmune diseases. Jasper was founded out of Stanford and JSP-191 was invented and developed at Amgen. In May 2021 the company merged with Amplitude Healthcare Acquisition Corporation and listed on Nasdaq with the ticker JSPR.